Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021-Reference-Cited by-同舟云学术

Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021

Published:2022-11-17 Issue:46 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Kinross Pete¹²,Gagliotti Carlo¹³,Merk Hanna²,Plachouras Diamantis²,Monnet Dominique L²,Högberg Liselotte Diaz²,

Affiliation:

1. These authors contributed equally to the article and share first authorship.

2. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

3. Regional Agency for Health and Social Care of Emilia-Romagna, Bologna, Italy

Abstract

Recent data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) show a large increase of +57% in Acinetobacter species bloodstream infections in the European Union and European Economic Area in the first years of the COVID-19 pandemic (2020–2021) compared with 2018–2019. Most were resistant to carbapenems, from intensive care units, and in countries with ≥ 50% carbapenem resistance in Acinetobacter spp. in 2018–2019. This highlights the requirement for reinforced Acinetobacter preparedness and infection prevention and control in Europe.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference24 articles.

1. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings – 8 December 2016. Stockholm: ECDC, 2016 Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-carbapenem-resistant-acinetobacter-baumannii-healthcare

2. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual epidemiological report for 2021. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/report

3. European Centre for Disease Prevention and Control (ECDC). TESSy – The European Surveillance System – antimicrobial resistance (AMR) reporting protocol 2022 – European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance data for 2021. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/ears-net-reporting-protocol-2022

4. European Centre for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases. Stockholm: ECDC; 2022. Date accessed: 25 October 2022. Available from: https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases

5. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.;Murray;Lancet,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for mortality in Acinetobacter baumannii bloodstream infections and development of a predictive mortality model;Journal of Global Antimicrobial Resistance;2024-09

2. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy;Antimicrobial Resistance & Infection Control;2024-08-26

3. Differences in the epidemiology, clinical characteristics, distribution of microorganisms and outcomes between COVID-19 patients and non-COVID-19 patients with ICU- associated BSIs: a one-center retrospective study;2024-08-09

4. Evidence of Correlation between Membrane Phase Transition and Clonogenicity in Dehydrating Acinetobacter baumannii: A Combined Micro-Raman and AFM Study;The Journal of Physical Chemistry B;2024-07-03

5. Impact of COVID-19 on healthcare-associated infections and antimicrobial use in Italy, 2022;Journal of Hospital Infection;2024-07